Altimmune Inc (ALT)

04:27 AM

Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification - GuruFocus

04:27 AM

03:09 AM

Altimmune (ALT) Advances Liver Disease Focus with Pemvidutide - GuruFocus

03:09 AM

01:06 AM

Altimmune Q4 2025 Earnings Call Transcript - MarketBeat

01:06 AM

01:03 AM

Altimmune (ALT) Shares Drop Despite Breakthrough Therapy Plans - GuruFocus

01:03 AM

12:44 PM

William Blair reiterates Altimmune stock rating on trial data - Investing.com

12:44 PM

12:17 PM

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits

12:17 PM

11:49 AM

Altimmune to start MASH late-stage trial in 2026 (ALT:NASDAQ) - Seeking Alpha

11:49 AM

11:46 AM

Altimmune (ALT) Q4 2025 Earnings Call Transcript - The Globe and Mail

11:46 AM

09:59 AM

Earnings call transcript: Altimmune Inc. misses Q4 2025 expectations, stock declines - Investing.com

09:59 AM

09:02 AM

Altimmune Reports 2025 Financial Results and Clinical Trial Progress with New Partnerships Formed - geneonline.com

09:02 AM

08:01 AM

Altimmune earnings missed by $0.02, revenue fell short of estimates - Investing.com

08:01 AM

07:44 AM

Altimmune (ALT) Reports Increased Revenue and Advances in Liver Disease Treatment - GuruFocus

07:44 AM

07:35 AM

ALTIMMUNE ($ALT) Releases Q4 2025 Earnings - Quiver Quantitative

07:35 AM

07:14 AM

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates - The Manila Times

07:14 AM

07:13 AM

Altimmune stock edges down on fourth quarter earnings miss By Investing.com - Investing.com UK

07:13 AM

07:11 AM

Altimmune stock edges down on fourth quarter earnings miss - Investing.com India

07:11 AM

Mar 04, 2026

Altimmune (ALT) Set to Release Q4 Earnings with Anticipated EPS of -$0.24 - GuruFocus

Mar 04, 2026

Mar 04, 2026

What to Expect from Altimmune's Earnings - Benzinga

Mar 04, 2026

Mar 02, 2026

Altimmune to Participate in Upcoming Investor Conferences - Bitget

Mar 02, 2026

Mar 02, 2026

Altimmune, Inc. Announces Participation in Upcoming Investor Conferences Addressing Serious Liver Diseases - Quiver Quantitative

Mar 02, 2026

Mar 01, 2026

(ALT.O) | Stock Price & Latest News - Reuters

Mar 01, 2026

Feb 28, 2026

ALT Should I Buy - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Altimmune (ALT) CSO receives stock option and RSU equity awards - Stock Titan

Feb 27, 2026

Feb 27, 2026

Altimmune (ALT) grants CFO 259,000 options and 111,000 RSUs - Stock Titan

Feb 27, 2026

Feb 27, 2026

Altimmune, Inc. (ALT) Stock Analysis: Exploring a Potential 296% Upside in Biotech Investments - DirectorsTalk Interviews

Feb 27, 2026

Feb 26, 2026

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play - Nasdaq

Feb 26, 2026

Feb 26, 2026

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - The Manila Times

Feb 26, 2026

Feb 24, 2026

Altimmune Inc (ALT.US) Stock Price, News & Analyst Forecast - eToro

Feb 24, 2026

Feb 23, 2026

Altimmune Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

Feb 23, 2026

Feb 21, 2026

Aug Sectors: Does Altimmune Inc have pricing powerLayoff News & Fast Moving Market Watchlists - baoquankhu1.vn

Feb 21, 2026

Feb 20, 2026

Altimmune CEO Jerry Durso strengthens company foundation for liver disease mission - Traders Union

Feb 20, 2026

Feb 20, 2026

Altimmune, Inc. (ALT) Stock Analysis: Eyeing A Potential 293% Upside In The Biotech Space - DirectorsTalk Interviews

Feb 20, 2026

Feb 19, 2026

Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Feb 19, 2026

Feb 17, 2026

Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances - Finviz

Feb 17, 2026

Feb 17, 2026

MSN Money - MSN

Feb 17, 2026

Feb 15, 2026

Is Altimmune Inc. stock a good pick for beginnersWeekly Investment Report & Free Community Supported Trade Ideas - mfd.ru

Feb 15, 2026

Feb 14, 2026

Why Altimmune Inc. stock is trending among retail tradersEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru

Feb 14, 2026

Feb 13, 2026

Altimmune, Inc. (ALT) Stock Analysis: Exploring A Potential 286% Upside In Biotechnology - DirectorsTalk Interviews

Feb 13, 2026

Feb 11, 2026

Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 11, 2026

Feb 10, 2026

Altimmune gains on FDA breakthrough designation for MASH therapy - MSN

Feb 10, 2026

Feb 05, 2026

Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases - Quiver Quantitative

Feb 05, 2026

Feb 04, 2026

Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development - MSN

Feb 04, 2026

Feb 04, 2026

Altimmune Sets 2026 Annual Stockholder Meeting Timeline - The Globe and Mail

Feb 04, 2026

Feb 03, 2026

Is Altimmune Inc a strong candidate for buy and hold2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn

Feb 03, 2026

Feb 03, 2026

Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha

Feb 03, 2026

Feb 02, 2026

Forecast Cut: Is Altimmune Inc a strong candidate for buy and holdTake Profit & Smart Swing Trading Techniques - baoquankhu1.vn

Feb 02, 2026

Feb 02, 2026

Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Insider Monkey

Feb 02, 2026

Feb 01, 2026

Growth Report: Is Altimmune Inc a strong candidate for buy and holdJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn

Feb 01, 2026

Jan 31, 2026

Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock²

Jan 31, 2026

Jan 30, 2026

Altimmune, Inc. (ALT) Stock Analysis: Exploring a 246% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Jan 30, 2026